Zobrazeno 1 - 10
of 117
pro vyhledávání: '"E K, Rowinsky"'
Autor:
E. K. Rowinsky
Publikováno v:
The Oncologist. 8:5-17
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10205579229603da02e38a2445f57ccc
https://doi.org/10.1634/theoncologist.8-2004-5
https://doi.org/10.1634/theoncologist.8-2004-5
Autor:
E. K. Rowinsky
Publikováno v:
The Oncologist. 8:1-4
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dff0bfec3e9222ab22e5e7e870a44810
https://doi.org/10.1634/theoncologist.8-2004-1
https://doi.org/10.1634/theoncologist.8-2004-1
Autor:
E. Campbell, J. G. Kuhn, Anthony W. Tolcher, J. Rizzo, Geoffrey R. Weiss, Elzbieta Izbicka, E. K. Rowinsky, C. Aylesworth, D. D. Von Hoff
Publikováno v:
Annals of Oncology. 11:333-338
Summary Background; Rhizoxin (NSC 332598) is a novel macrolide antitumor antibiotic that inhibits microtubule assembly and also depolymerizes preformed microtubules. In preclinical evaluations, rhizoxin demonstrated broad antitumor activity in vitro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17f9358ed3042c55af7ac8c637a015aa
https://doi.org/10.1023/a:1008398725442
https://doi.org/10.1023/a:1008398725442
Autor:
D. D. Von Hoff, Eric Raymond, E. K. Rowinsky, Axel-R. Hanauske, Gary M. Clark, Sandrine Faivre, Elzbieta Izbicka
Publikováno v:
Anti-Cancer Drugs. 8:379-385
Paclitaxel shows a broad clinical activity in ovarian, breast and non-small cell lung cancers. However, controversy remains about the respective effects of doses and schedules in paclitaxel cytotoxicity. This study was conducted to compare the cytoto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba808d26b591f439f7eaa7cea4ccf63e
https://doi.org/10.1097/00001813-199704000-00011
https://doi.org/10.1097/00001813-199704000-00011
Autor:
Michael T. Crow, Edward G. Lakatta, E K Rowinsky, Rebecca R. Pauly, Jeffrey P. Froehlich, Robert E. Monticone, Masafumi Kuzuya, Linda Cheng, Steven J. Sollott, G M Jenkins
Publikováno v:
Journal of Clinical Investigation. 95:1869-1876
Despite significant improvements in the primary success rate of the medical and surgical treatments for atherosclerotic disease, including angioplasty, bypass grafting, and endarterectomy, secondary failure due to late restenosis continues to occur i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2f44e66e3792d697a66dd20c566c2018
https://doi.org/10.1172/jci117867
https://doi.org/10.1172/jci117867
Autor:
Jennifer L. Spratlin, Roger B. Cohen, S. Gail Eckhardt, Laura Q.M. Chow, Matthew Eadens, Cindy L. O'Bryant, E. K. Rowinsky, Nancy L. Lewis, E. Gabriela Chiorean, Natalie J. Serkova, Lia Gore, Sami Diab, D. Ross Camidge, Stephen Leong, N. J. Meropol, Floyd Fox, Hagop Youssoufian
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 28(5)
Purpose To evaluate the safety, maximum-tolerated dose (MTD), pharmacokinetics (PKs), pharmacodynamics, and preliminary anticancer activity of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7e8197864230e3ad32fbb4193a3d5745
https://pubmed.ncbi.nlm.nih.gov/20048182
https://pubmed.ncbi.nlm.nih.gov/20048182
Publikováno v:
Blood. 75:1319-1323
Bryostatin 1, a macrocyclic lactone isolated from the marine bryozoan Bugula neritina, has demonstrated both antineoplastic activity against the murine P388 leukemia line in vivo and stimulatory activity against mouse and human hematopoietic progenit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::43fd79f14303ed7471de192537bd9916
https://doi.org/10.1182/blood.v75.6.1319.1319
https://doi.org/10.1182/blood.v75.6.1319.1319
Autor:
F A, Holmes, E K, Rowinsky
Publikováno v:
Seminars in oncology. 28(4 Suppl 12)
Paclitaxel and docetaxel each possess unique chemical and pharmacologic characteristics that account for significant differences in their potencies, toxicologic and pharmacokinetic profiles, and propensity for drug-drug interactions. Results from pha
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3d7f878d3a67956daabbfca45b806a2b
https://pubmed.ncbi.nlm.nih.gov/11552225
https://pubmed.ncbi.nlm.nih.gov/11552225
Autor:
S D, Gore, L J, Weng, S, Zhai, W D, Figg, R C, Donehower, G J, Dover, M, Grever, C A, Griffin, L B, Grochow, E K, Rowinsky, Y, Zabalena, A L, Hawkins, K, Burks, C B, Miller
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(8)
Sodium phenylbutyrate (PB) is an aromatic fatty acid with cytostatic and differentiating activity against malignant myeloid cells (ID(50), 1-2 mM). Higher doses induce apoptosis. Patients with myelodysplasia (n = 11) and acute myeloid leukemia (n = 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::903531dce5e6b008e1c5edba027d006a
https://pubmed.ncbi.nlm.nih.gov/11489809
https://pubmed.ncbi.nlm.nih.gov/11489809
Autor:
G, Schwartz, T R, Johnson, A, Goetz, H, Burris, L, Smetzer, T, Lampkin, J, Sailstad, J A, Hohneker, D D, Von Hoff, E K, Rowinsky
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 7(7)
This study was performed to assess the feasibility of administering 1843U89, a potent, noncompetitive inhibitor of thymidylate synthase that does not require polyglutamation for activity, as a 2-min i.v. infusion daily for 5 days every 3 weeks, to de
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9e7b2cb5dc44a518af5d996cac4d6f92
https://pubmed.ncbi.nlm.nih.gov/11448903
https://pubmed.ncbi.nlm.nih.gov/11448903